EP2514415A1 — Transdermally absorbed preparation of anti-dementia drug
Assigned to Teikoku Seiyaku Co Ltd · Expires 2012-10-24 · 14y expired
What this patent protects
The present invention relates to a percutaneous absorption preparation which can administer an anti-dementia drug stably and efficiently for a long period such as one week. More specifically, the present invention relates to a percutaneous absorption preparation comprising a drug…
USPTO Abstract
The present invention relates to a percutaneous absorption preparation which can administer an anti-dementia drug stably and efficiently for a long period such as one week. More specifically, the present invention relates to a percutaneous absorption preparation comprising a drug-containing layer comprising an anti-dementia drug, a polymer compound having an amino group, a polyhydric alcohol fatty acid ester, a polyhydric alcohol, a polyvalent carboxylate ester, and a styrenic polymer compound.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.